InsiderTrades

Form 4 for FATE FATE THERAPEUTICS INC

Accepted 2022-01-24 00:00:00 ET · period of report 2022-01-20 · accession 0001209191-22-004606 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-01-24 2022-01-20+ FATE Wolchko J Scott Pres, CEO, Dir S - Sale+OE $39.66 -40.0K 431.5K -8% -$1.59M
DM 2022-01-24 2022-01-20+ FATE Wolchko J Scott Pres, CEO, Dir M - OptEx $2.72 +40.0K 461.5K +9% +$108.9K
DM 2022-01-24 2022-01-20+ FATE Wolchko J Scott Pres, CEO, Dir M - OptEx $2.72 -40.0K 20.0K -67% -$108.9K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-01-21 S D 10,000 $38.02 431,546 D — —
2 Common Common Stock 2022-01-21 M A 10,000 $2.70 441,546 D — —
3 Common Common Stock 2022-01-20 S D 30,000 $40.21 431,546 D — —
4 Common Common Stock 2022-01-20 M A 30,000 $2.73 461,546 D — —
5 Derivative Stock Option (Right to Buy) 2022-01-21 M D 10,000 $2.70 89,446 D $2.70 · — to 2026-01-11 10,000 Common Stock (F2) This option is fully vested.
6 Derivative Stock Option (Right to Buy) 2022-01-20 M D 30,000 $2.73 20,000 D $2.73 · — to 2027-01-03 30,000 Common Stock (F2) This option is fully vested.